Moderna raises 2021 Covid-19 vaccine output forecast to at least 600 million doses

Moderna Inc said on Monday it would produce at least 600 million doses of its Covid-19 vaccine in 2021, up by 100 million doses from its previous forecast, as the United States continues to roll-out the vaccine.

The company was working to invest and hire in order to deliver up to 1 billion doses this year, the higher end of its production forecast, it said.

Moderna said it has so far supplied about 18 million doses to the U.S. government as part of a deal for 200 million doses. It has also signed a deal with the Canadian government for 40 million doses.

Related Posts

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Meiji Seika to push new vaccine with SII in India

Meiji Seika to push new vaccine with SII in India

DGFT automates EO extension process to ease compliance for pharma exporters

DGFT automates EO extension process to ease compliance for pharma exporters

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

Three newborns die in fire at government hospital in Amravati, Maharashtra

Three newborns die in fire at government hospital in Amravati, Maharashtra

Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

Centre bans fixed-dose combination for Common Cold in children below four

Centre bans fixed-dose combination for Common Cold in children below four